Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  peginterferon alfa-2b
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-16 of 16 for your search:
Start Over
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: daliah2011, NCT01387763
Adjuvant PEG Intron in Ulcerated Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EORTC-18081, 2009-010273-20, NCT01502696
Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CML V, 2010-024262-22, NCT01657604
Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: VEMUPLINT, NCT01959633
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-029, 2013-004072-36, NCT02089685
Peginterferon and TIL Therapy for Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MM1413, NCT02379195
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GU-071, 14-052, NCT02447887
Study of PEG-Intron for Plexiform Neurofibromas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 months to 21 years
Sponsor: NCI, Other
Protocol IDs: UPCI 06-116, NCT00396019
Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: NordCML007, 2011-005989-38, NCT01725204
Nilotinib Plus Pegylated Interferon-a2b in CML
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NordDutchCML009, 2012-004321-25, NTR 3732, NCT01866553
Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 months to 25 years
Sponsor: NCI, Other
Protocol IDs: PBTC-039, NCI-2013-01639, U01CA081457, NCT01964300
Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17759, NCT02218164
PEG-Intron for Recurrent or Refractory Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: IRB00074563, NCT02343224
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13-105, NCT02112032
An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Merck MISP 50422, NCT01986712
Start Over